Logo image of EVO

EVOTEC SE - SPON ADR (EVO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EVO - US30050E1055 - ADR

3.26 USD
+0.03 (+0.93%)
Last: 11/26/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, EVO scores 2 out of 10 in our fundamental rating. EVO was compared to 58 industry peers in the Life Sciences Tools & Services industry. EVO has a bad profitability rating. Also its financial health evaluation is rather negative. EVO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EVO has reported negative net income.
EVO had a positive operating cash flow in the past year.
In multiple years EVO reported negative net income over the last 5 years.
In the past 5 years EVO always reported a positive cash flow from operatings.
EVO Yearly Net Income VS EBIT VS OCF VS FCFEVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of EVO (-8.97%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -19.87%, EVO is in line with its industry, outperforming 48.28% of the companies in the same industry.
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVO Yearly ROA, ROE, ROICEVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

EVO has a Gross Margin of 10.82%. This is amonst the worse of the industry: EVO underperforms 84.48% of its industry peers.
In the last couple of years the Gross Margin of EVO has declined.
EVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVO Yearly Profit, Operating, Gross MarginsEVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

3

2. Health

2.1 Basic Checks

EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
EVO has more shares outstanding than it did 1 year ago.
EVO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EVO has been reduced compared to a year ago.
EVO Yearly Shares OutstandingEVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EVO Yearly Total Debt VS Total AssetsEVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

EVO has an Altman-Z score of 0.52. This is a bad value and indicates that EVO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.52, EVO is not doing good in the industry: 70.69% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.48 indicates that EVO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.48, EVO is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z 0.52
ROIC/WACCN/A
WACC7.12%
EVO Yearly LT Debt VS Equity VS FCFEVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 2.12 indicates that EVO has no problem at all paying its short term obligations.
The Current ratio of EVO (2.12) is comparable to the rest of the industry.
EVO has a Quick Ratio of 2.03. This indicates that EVO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.03, EVO perfoms like the industry average, outperforming 44.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 2.03
EVO Yearly Current Assets VS Current LiabilitesEVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for EVO have decreased strongly by -136.17% in the last year.
Looking at the last year, EVO shows a decrease in Revenue. The Revenue has decreased by -2.67% in the last year.
The Revenue has been growing by 12.29% on average over the past years. This is quite good.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%

3.2 Future

EVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.75% yearly.
The Revenue is expected to grow by 6.85% on average over the next years.
EPS Next Y59.73%
EPS Next 2Y35.6%
EPS Next 3Y28%
EPS Next 5Y19.75%
Revenue Next Year-2.27%
Revenue Next 2Y4.05%
Revenue Next 3Y6.5%
Revenue Next 5Y6.85%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EVO Yearly Revenue VS EstimatesEVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
EVO Yearly EPS VS EstimatesEVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVO. In the last year negative earnings were reported.
Also next year EVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVO Price Earnings VS Forward Price EarningsEVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

EVO's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 634.75
EVO Per share dataEVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as EVO's earnings are expected to grow with 28.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.6%
EPS Next 3Y28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOTEC SE - SPON ADR

NASDAQ:EVO (11/26/2025, 8:00:01 PM)

3.26

+0.03 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)N/A N/A
Inst Owners60.42%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.16B
Revenue(TTM)756.33M
Net Income(TTM)-158.98M
Analysts78.46
Price Target5.27 (61.66%)
Short Float %0.14%
Short Ratio7.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-64.24%
Min EPS beat(2)-106.63%
Max EPS beat(2)-21.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.97%
Min Revenue beat(2)-9.17%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.99%
Min Revenue beat(4)-9.17%
Max Revenue beat(4)-0.93%
Revenue beat(8)1
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)1.12%
Revenue beat(16)7
Avg Revenue beat(16)2.95%
PT rev (1m)-4.91%
PT rev (3m)-4.79%
EPS NQ rev (1m)733.6%
EPS NQ rev (3m)733.6%
EPS NY rev (1m)5.45%
EPS NY rev (3m)5.04%
Revenue NQ rev (1m)4.39%
Revenue NQ rev (3m)6.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.32
P/FCF N/A
P/OCF 709.19
P/B 1.25
P/tB 2
EV/EBITDA 634.75
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)0
OCFY0.14%
SpS2.47
BVpS2.61
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.82%
FCFM N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA 209.82
Cap/Depr 90.72%
Cap/Sales 12.19%
Interest Coverage N/A
Cash Conversion 76.3%
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 2.03
Altman-Z 0.52
F-Score4
WACC7.12%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y59.73%
EPS Next 2Y35.6%
EPS Next 3Y28%
EPS Next 5Y19.75%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
Revenue Next Year-2.27%
Revenue Next 2Y4.05%
Revenue Next 3Y6.5%
Revenue Next 5Y6.85%
EBIT growth 1Y-6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.47%
EBIT Next 3Y50.57%
EBIT Next 5Y33.86%
FCF growth 1Y52.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y107.69%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%

EVOTEC SE - SPON ADR / EVO FAQ

Can you provide the ChartMill fundamental rating for EVOTEC SE - SPON ADR?

ChartMill assigns a fundamental rating of 2 / 10 to EVO.


What is the valuation status for EVO stock?

ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE - SPON ADR (EVO). This can be considered as Overvalued.


How profitable is EVOTEC SE - SPON ADR (EVO) stock?

EVOTEC SE - SPON ADR (EVO) has a profitability rating of 2 / 10.


What is the financial health of EVOTEC SE - SPON ADR (EVO) stock?

The financial health rating of EVOTEC SE - SPON ADR (EVO) is 3 / 10.